Biotech Stocks Facing FDA Decision In August 2024

(RTTNews) - As August approaches, it's time for our regular review of the critical FDA decisions on the horizon.

So far this year, 22 novel drugs have been approved by the FDA compared to 29 during the same period last year. ("Novel" drugs are new drugs never before approved or marketed in the U.S.: Source: FDA).

Separately, August is observed as spinal muscular atrophy (SMA) awareness month. SMA is a rare genetic neurodegenerative disorder characterized by the loss of motor neurons, atrophy of the voluntary muscles of the limbs and trunk and progressive muscle weakness.

Typically, fatal and commonly diagnosed in young children, SMA has no complete cure. However, approved therapies can manage the symptoms of this neuromuscular disease. Notable treatments include Biogen's Spinraza, Novartis' Zolgensma, and Roche's Evrysdi.

Now, let's take a look at the biotech stocks facing FDA decision in August.